cells

MDPI

Correction

Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. *Cells* 2022, *11*, 2107

Harinder Gill

Department of Medicine, LKS Faculty of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China; gillhsh@hku.hk; Tel.: +852-22554542

Text Correction

The authors would like to make the following corrections to the published paper [1]:

The acknowledgments are missing. Bomedemstat, the most successful LSD1 inhibitor, was developed by Dr. Hugh Y Rienhoff and his team at Imago Biosciences, and many ideas in this review were inspired by Dr. Rienhoff and his story. Therefore, the author feels a strong need to acknowledge them in a correction notice. The corrected acknowledgments should read as follows:

Acknowledgments: The author would like to acknowledge Hugh Young Rienhoff and his team at Imago Biosciences for their work on the role of LSD1 and the development of IMG-7289 (Bomedemstat), which inspired this manuscript.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. *Cells* **2022**, *11*, 2107. [CrossRef] [PubMed]

check for updates

Citation: Gill, H. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. *Cells* 2022, *11*, 2107. *Cells* **2022**, *11*, 4126. https://doi.org/10.3390/cells11244126

Received: 26 September 2022
Accepted: 30 September 2022
Published: 19 December 2022